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Alzheimer’s disease (AD) is a genetically complex and heterogeneous disorder. To date four genes have been established to either cause
early-onset autosomal-dominant AD (APP, PSEN1, and PSEN21–4) or to increase susceptibility for late-onset AD (APOE5). However, the
heritability of late-onset AD is as high as 80%,6 and much of the phenotypic variance remains unexplained to date. We performed a
genome-wide association (GWA) analysis using 484,522 single-nucleotide polymorphisms (SNPs) on a large (1,376 samples from 410
families) sample of AD families of self-reported European descent. We identiﬁed ﬁve SNPs showing either signiﬁcant or marginally
signiﬁcant genome-wide association with a multivariate phenotype combining affection status and onset age. One of these signals
(p ¼ 5.7 3 1014) was elicited by SNP rs4420638 and probably reﬂects APOE-34, which maps 11 kb proximal (r2 ¼ 0.78). The other
four signals were tested in three additional independent AD family samples composed of nearly 2700 individuals from almost 900 fam-
ilies. Two of these SNPs showed signiﬁcant association in the replication samples (combined p values 0.007 and 0.00002). The SNP
(rs11159647, on chromosome 14q31) with the strongest association signal also showed evidence of association with the same allele
in GWA data generated in an independent sample of ~1,400 AD cases and controls (p ¼ 0.04). Although the precise identity of the un-
derlying locus(i) remains elusive, our study provides compelling evidence for the existence of at least one previously undescribed AD
gene that, like APOE-34, primarily acts as a modiﬁer of onset age.In contrast to early-onset autosomal-dominant Alz-
heimer’s disease (AD [MIM 104300]), late-onset AD usually
shows less obvious or no apparent familial aggregation
(‘‘sporadic AD’’). Risk for late-onset AD is probably inﬂu-
enced by an array of common risk alleles distributed across
different genes affecting a variety of biochemical pathways
affecting both the etiology and pathogenesis of AD.
Although the identity and total number of these genes
remain elusive, recent estimates suggest that together
they have a large impact on disease predisposition in the
general population.6 In the attempt to identify the remain-
ing AD susceptibility genes, a large body of evidence has
accrued over the past 30 years, represented by well over
1000 publications genetically implicating or excluding po-
tential risk factors, the vast majority of which were tested
as functional and/or positional candidate genes.7 How-
ever, with the exception of the 34-allele of APOE (MIM
107741), these efforts have mostly led to inconsistent ﬁnd-
ings, although some polymorphisms show signiﬁcant but
modest (~1.25) summary odds ratios by meta-analysis
(for an up-to-date overview of AD genetic association stud-
ies see the ‘‘AlzGene’’ database7). Recently, three genome-
wide association analyses, all using case-control designs,
have been published for AD.8–10 All three studies detectedThe Americahighly signiﬁcant association at the APOE locus. In
addition, they reported the discovery of a number of addi-
tional putative AD variants of small effect size, which await
independent replication by other groups.7 Here, we set out
to identify additional AD genes by performing whole-
genome association analysis using 500,668 SNPs on the
GeneChip Human Mapping 500K Array Set (Affymetrix,
Santa Clara, CA, USA) in four well-characterized samples
of AD families.
All data sets tested in this project were originally
collected for the study of genetic factors in AD with fam-
ily-based methods (see Table S1 available online for a de-
tailed summary of sample characteristics). All studies
were approved by the institutional review boards of the ap-
propriate institutions, and all subjects gave informed con-
sent for their participation.With the exception of the CAG
sample (see below), themajority of pedigrees analyzed here
were nuclear families ascertained on the basis of multiple
affecteds, generally lacking parental genotypes. In addition
to containing at least one affected relative pair, many ped-
igrees also had DNA available from additional affected or
unaffected individuals. These were mostly siblings, and
only a minority of additional subjects stemmed from
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NIMH sample). The diagnosis of ‘‘deﬁnite,’’ ‘‘probable,’’ or
‘‘possible’’ AD was made according to NINCDS/ADRDA11
criteria in all samples. Age of onset for all AD cases was
determined by a clinician on the basis of an interview
with a knowledgeable informant and review of any avail-
able records.
NIMH Families
This sample was collected as part of the National Institute
of Mental Health Genetics Initiative Study12 and com-
prised a total of 1528 subjects from 457 families. Only fam-
ilies in which all affected family members showed an onset
age R50 years, and in which DNA was available from at
least two affected family members, were included in these
analyses, i.e., 1439 individuals from 436 families. Of these,
1376 individuals from 410 families were of self-reported
European ancestry and used for the initial 500K screening.
Fifty-eight individuals from 24 families were of African
descent and were included in the follow-up analyses.
NIA and NCRAD Families
Both of these data sets were obtained from the National
Repository of Research on Alzheimer’s Disease (NCRAD),
and ascertainment and collection details can be found at
the NCRAD website. For this study, we used families of
self-reported European ancestry with DNA available from
at least two ﬁrst-degree relatives (concordant or discordant)
and in which all individuals affected with AD showed
onset ages R50 years. For the NIA collection, this com-
prised 1040 samples from 329 pedigrees, and for NCRAD,
this comprised 1108 samples from 331 pedigrees.
CAG Families
Samples in this data set were recruited under the auspices
of the ‘‘Consortium on Alzheimer’s Genetics’’ (see Bertram
et al.13 for more details). Probands were included only if
they had at least one unaffected living sibling willing to
participate in this study. As for the other replication
samples, only families of self-reported European ancestry
and with onset ages R50 years were included here, i.e.,
483 individuals from 215 sibships.
We genotyped 500,668 SNPs of the GeneChip Human
Mapping 500K Array Set in 1505 individuals comprising
the publicly available NIMH AD genetics population,
using two chips (Nsp and Sty) that each assayed approxi-
mately 250,000 SNPs per sample. Modiﬁcations to the
manufacturer’s protocol (see below and Supplemental
Data) increased the quality and quantity of data obtained
from each chip assay. Genotyping was carried out accord-
ing to the manufacturer’s protocol except for the
following modiﬁcations: Restriction enzyme digestion,
ligation, PCR, and puriﬁcation were completed in 96-well
plates containing 92 samples and four blanks. The PCR
normalization step was performed with a Biomek F/X
robot. After normalization, PCR products were divided
into four separate 96-well plates each containing only 23
samples. Both the fragmentation and labeling steps were624 The American Journal of Human Genetics 83, 623–632, Novembperformed on 23 samples at a time, while a constant tem-
perature with cold blocks was maintained. For the hybrid-
ization step, samples were denatured in hybridization
cocktail for 10 min at 99C and 2 min at 49C with an
MJ Tetrad, then transferred immediately to an external
heating block kept at a constant temperature of 49C. Prior
to sample injection, the 500K arrays were warmed in hy-
bridization ovens at 49C for at least 10 min. During sam-
ple injection the arrays were maintained at 40C–49C and
were immediately returned to the hybridization oven for
19 to 27 hr of incubation at 49C. Posthybridization
wash, staining, and detection were performed in accor-
dance with the manufacturer’s protocol. The average call
rates increased from 87.5% to 97.3% and from 94.8% to
96.1% for Nsp and Sty arrays, respectively. Out of the en-
tire sample, data from only eight arrays on a total of ﬁve
DNA samples failed to exceed a 93% call-rate threshold
necessary to be included in the analyses. Genotype calls
were based on the Bayesian Robust Linear Model with Ma-
halanobis Distance algorithm (BRLMM14) for which we de-
veloped an improved protocol that led to greater call rates
without affecting accuracy or reproducibility of the data
and that was used here (see below). Overall, our protocol
achieved an average SNP genotype call rate of 98.95%.
SNPs with genotype call rates below 90% (5758 markers
[1.1%]) were excluded. In addition, we excluded all SNPs
located on the X chromosome (10,388 markers [2.1%],
resulting in 484,522 markers used in the whole-genome
association analyses. SNPs on the X chromosome were
excluded because there is currently no method available
for association testing of these markers in family-based
settings.
We accepted only genotype calls passing a stringent
quality-control threshold in which 93% of the SNPs on
a 250K array yielded a genotype (with the DM algorithm
at a conﬁdence threshold of 0.33). Of the 3010 500K Gene-
Chips necessary to complete genotyping of our family-
based sample set, only eight chips failed to meet or exceed
the 93% call-rate threshold. The DM algorithm calculates
genotypes for one sample at a time, relying on assump-
tions about the behavior of SNP allele signals. However,
an alternative genotype-calling algorithm was recently de-
veloped by Rabbee and Speed termed Bayesian Robust Lin-
ear Modeling using Mahalanobis Distance (BRLMM14).
The BRLMM method simultaneously analyzes data from
multiple chips, by calling genotypes via multiple-sample
cluster analysis. BRLMM accounts for probe effects on
variation in allele signal intensity of individual SNPs in
making genotype calls. This new algorithm is an improve-
ment over DM in terms of overall call rates, accuracy, and
detection of heterozygous genotypes. Both Affymetrix and
The Broad Institute (MIT/Harvard) have shown improved
efﬁcacy of genotyping calling by using BRLMM on their
data sets.
We compared the DM and BRLMM genotype-calling al-
gorithms with respect to call rates, accuracy, and concor-
dance on our 500K data set. Initial analysis of our dataer 7, 2008
with BRLMM increased the number of heterozygous geno-
types (Figure S1), as well as the total number of genotypes
called (data not shown). Accuracy of called genotypes was
assessed via inheritance-error checks on replicate data with
varying DM-derived call rates, collected for a family trio
(mother, father, and child) contained in our data set.
Inheritance errors consistently decreased with increasing
initial DM call rate (Table S2), and even fewer inheritance
errors were observed when BRLMM analysis was applied.
Overall, genotype calls made by DM and BRLMM were in
close agreement with one another, and the concordance
increased with data from chips having higher initial DM
call rates, indicating that higher call-rate data is more
reliable (Figure S2A). Although BRLMM was able to make
calls on a signiﬁcant number of SNPs that were previously
not called with DM, we did observe the reverse scenario
as well, albeit with a much lower number of SNPs
(Figure S2B).
Because the BRLMM algorithm processes chips in
batches and uses a clustering algorithm to make genotype
calls, we determined whether batch size and/or batch com-
position had an effect on call rate. Experiments were car-
ried out with batch sizes of 50 and 100 chip-data CEL ﬁles.
We tested samples with moderate (93%), good (95%), and
excellent (98%) chip call rates1 and processed them in
varying batch environments. Single test samples (e.g.,
93% initial DM call rate) were grouped with samples that
had (1) like or similar call rates (e.g., 93%), (2) mixed call
rates (samples with call rates ranging between 93% and
99%), or (3) unlike or dissimilar call rates (e.g., 98%). CEL
data ﬁles were analyzed in ‘‘like,’’ ‘‘mixed,’’ and ‘‘unlike’’
environments with the BRLMM algorithm. The ‘‘mixed’’
environment was designed to emulate the batch composi-
tion one would obtain if processing batches were built ran-
domly. Contrary to our expectations, we found that batch
context does make a difference in genotype calling efﬁ-
cacy. Speciﬁcally, we observed that call rates for the test
samples were substantially improved when processed
with data ﬁles of similar call rates (Figure S3). Themost dra-
matic results were observed with samples at the lower end
of the range of DM call rates tested, those with ‘‘moderate’’
call rates (93%). For example, when a sample with amoder-
ate DM call rate was called in a batch environment
composed ofmoderate DM call-rate samples, chip call rates
were boosted substantially. Chip call rates for these sam-
ples were consistently superior in the ‘‘like’’ environment
rather than the ‘‘unlike,’’ boosting call rates on average
2.3%5 0.9%. In addition, the ‘‘like’’ environment consis-
tently outperformed the ‘‘mixed’’ environment, boosting
call rates on average 0.5%5 0.4%.
Chips from the ‘‘good’’ (95%) and ‘‘excellent’’ (98%) call-
rate1 classes showed a similar pattern to the ‘‘moderate’’
chips when analyzed in the three different batch environ-
ments with BRLMM; however, this trend was not absolute.
Themajority of the cases tested showed improved call rates
when analyzed in ‘‘like’’ environments as compared to
‘‘mixed’’ or ‘‘unlike’’ environments, with a few exceptionsThe America(Figure S3). To better understand this ‘‘batch-effect’’ phe-
nomenon, we investigated the properties of probe signals
for several SNPs in which a genotype was called in the
‘‘like’’ environment and not called in the ‘‘unlike’’ environ-
ment. For the SNPs of interest, the BRLMM-derived allele
signal for of all SNPs in the cluster of samples was trans-
formed into Cluster-Center-Stretch space (see the Affyme-
trix website and Figure S4). This example illustrates that
both the allele contrast and the signal strength can shift
markedly with different input data sets. Given this phe-
nomenon, it is clear that the contents of a data set can in-
ﬂuence the genotype-calling behavior for some outlying
samples. Indeed, it is evident in this example that the un-
called genotype (blue triangle, Figure S4B) fell well outside
of the expected cluster (pink triangles) and was thus not
called. Examination of several such examples showed
two trends that help explain the ineffectiveness of high
DM call-rate batches to call lower DM call-rate raw data:
(1) The genotype clusters for high DM call-rate data are
typically tighter than those from lower call-rate data. (2)
The signal strength (y axis) axis is generally higher for
high call-rate data. The differences observed underscore
the need to process CEL-data ﬁles in batches with similar
or mixed call rates, in order to create genotype-calling clus-
ters that are valid for all samples in the batch. These exper-
iments suggest that call-rate outcome with BRLMM can
vary, depending on the batch environment chosen for
analysis, and that careful attention to the batch selection
can improve the number of genotypes called by greater
than 2%. On the basis of the analysis above, we developed
a ‘‘workﬂow’’ for maximizing SNP call rates while main-
taining high accuracy and reproducibility of our data. We
used DM as an initial quality measure for individual chips
and then reanalyzed the raw data with the BRLMM algo-
rithm in appropriately deﬁned clusters. With this method,
the average chip call rates across the entire sample set
improved to 98.95% with BRLMM (Figure S5) with over
half of the chips yielding genotype calls for greater than
99% of the SNPs assayed (Figure S5).
In addition to the chip-based genotypes, we also geno-
typed all four SNPs implied by the GWA analyses as well
as APOE SNPs rs429358 and rs7412 in all four samples
with high-efﬁciency ﬂuorescence polarization (HEFP)
detection of a single-base extension assay.15 The HEFP
procedures were essentially identical to those previously
described.13 Primer sequences and thermocycling condi-
tions are available on request. Neither genotyping method
showed evidence for Mendelian errors for these four SNPs,
although our power to detect such inconsistencies is low
because of the lack of parental genotypes (see above) and
relatively small family size.
Association analyses were performed with PBAT (v3.6),
an extension16 of the family-based association test (FBAT)
program.17 To maximize statistical power, we tested AD
affection status and age of onset jointly, using the multi-
variate extension of the FBAT-approach, FBAT-GEE.18 To
minimize the multiple testing problem, we applied then Journal of Human Genetics 83, 623–632, November 7, 2008 625
weighted Bonferroni-testing strategy by Ionita-Laza et al.19
which is an extension of the VanSteen algorithm.20 On the
basis of the between-family information that is statistically
independent from the FBAT-statistic,20 the testing strategy
evaluates the evidence for association at a population level
and then estimates the conditional power of the FBAT-GEE
statistic for eachmarker in the ﬁrst step. The FBAT-GEE sta-
tistic contains affection status and time to onset as pheno-
types, coded asWilcoxon statistic. The choice of which sta-
tistic to use in the association test is determined on the
basis of the highest conditional-power estimate for each
coding. In the second step of the testing strategy, FBAT sta-
tistics are computed for all markers. Because none of the
traits here were quantitative, the conditional power was es-
timated on the basis of the nonparametric extension of the
conditional mean model approach to dichotomous traits
and time-to-onset variables proposed by Jiang et al.21 Their
signiﬁcance is assessed on the basis of individually ad-
justed alpha levels that maintain the overall type 1 error
and that are weighted on the basis of the conditional-
power estimate for the corresponding marker according
to their conditional-power estimates. The computation of
the weights is described in detail in Ionita-Laza et al.19
Here, the approach was applied with the following tuning
parameters: The size of the ﬁrst partition was ﬁve and the
parameter was set to two. When the weighted Bonfer-
roni-approach was applied to the 809,208 p values of the
FBAT-GEE statistic for AD affection status and time to on-
set, four SNPs not related to APOE 34 reached genome-
wide signiﬁcance (thresholds for genome-wide signiﬁ-
cance are p % 5 3 103 for markers rs11159647,
rs179943, and rs2049161, and p % 4.88 3 106 for
rs3826656). Affection status was coded with an offset of
0.10 (approximate prevalence of AD among individuals
over 65 years). Sensitivity analyses using offsets ranging
from 0.05 to 0.2 did not change the results appreciably
(data not shown). The age of onset variable was con-
structed with the Wilcoxon approach.21 Although SNPs
on the X chromosome and those with low call rates or
poor reproducibility across duplicated genotypes were ex-
cluded from the analyses (16,146 SNPs), we retained
SNPs that deviated from HWE, which affected a total of
~85,000 SNPs at p ¼ 0.01, and ~56,000 at
p ¼ 0.001. Approximately half of the HWE-deviating
SNPs showed low minor allele frequencies (%0.10). Inclu-
sion of HWE-deviating SNPs was based on the assumption
that most departures from HWE in this context are caused
by miscalling heterozygous genotypes. Under these cir-
cumstances, dominant and recessive models, which treat
the heterozygous genotype and one of the homozygous
genotypes as one category, will provide test results that
are fairly robust against such genotyping errors. This was
the case for marker rs326656, which signiﬁcantly deviated
from HWE (p ¼ 1 3 1023) in the 500K data set, but not in
the families of the follow-up samples (all p values > 0.05),
which were genotyped with the HEFP technology (see
above). Regenotyping of this SNP by HEFP in the NIMH626 The American Journal of Human Genetics 83, 623–632, Novemfamilies resolved the HWE deviation (p ¼ 0.6), decreasing
the statistical signiﬁcance to p ¼ 0.04 in the FBAT-GEE
analyses. The FBAT-GEE test statistics were only calculated
for SNPs for which the number of informative families was
at least 20 (i.e. 404,604 out of the 484,522 SNPs with avail-
able genotypes). The 404,604 SNPs were tested under addi-
tive and dominant transmission models. Accordingly, all
nominal p values were adjusted conservatively for 2 3
404,604 = 809,208 comparisons, with the weighted Bon-
ferroni method by Ionita-Laza et al.13 We calculated p
values on the combined samples by using the method de-
scribed by Fisher22 taking into account the direction of the
transmissions in each individual sample. Pairwise LD esti-
mations were performed in Haploview (v3.32) on the 500K
SNP chip genotype data in self-reported European NIMH
families (using the regenotyped data for rs4777936) as
well as on genotype data available on the International
HapMap Consortium website (public release #22 based
on NCBI build 36 [dbSNP b126]).
In the ﬁrst stage of our project, we screened 1376 indi-
viduals from 410 families of self-reported European
descent from the National Institute of Mental Health
(NIMH) Genetics Initiative Study sample, the largest uni-
formly ascertained and evaluated AD family sample to
date.12,23 We optimized methods for both the genotyping
assay and genotype-calling algorithm that led to increased
quality and quantity of the data (see above). After removal
of all 10,388 X chromosomemarkers, as well as 5,758 SNPs
that did not pass genotype quality assessment or showed
a minor allele frequency (MAF) that resulted in less than
20 informative families, a total of 404,604 (80.8%) SNPs
were used for the whole-genome screening. Statistical anal-
yses were performed in PBAT with affection status and age
of onset as a multivariate phenotype in the FBAT-GEE
statistic for which p values were adjusted on the basis of
the weighted Bonferroni-testing strategy by Ionita-Laza
et al.19 The Q-Q plot displaying observed versus expected
p values shows that the overall alpha level is maintained,
despite a slight departure from the expected values for the
smallest p values (Figure 1). After correction for the num-
ber of tests performed, four markers not related to APOE
34 attained genome-wide signiﬁcance at an overall alpha
level of 5%. The ﬁrst marker, rs4420638 (p ¼ 5.7 3
1014), is located 340 bp 30 of APOC1 on chromosome
19q13 and very likely reﬂects the well-established effects
of the APOE 34-allele (rs429358), which maps 11 kb prox-
imal (r2 between both SNPs ¼ 0.78) and shows highly sig-
niﬁcant association in the NIMH families as well as the
three follow-up data sets (see below and Schjeide et al.24).
The other markers are rs11159647 (p ¼ 0.001; located in
predicted gene NT_026437.1360 on chromosome
14q31.2), rs179943 (p ¼ 0.002; in ATXN1 [MIM 601556]
on chromosome 6p22.3), rs3826656 (p¼ 43 106; located
in predicted gene NT_011109.848 on 19q13.33), and
rs2049161 (p ¼ 0.002; in cDNA BC040718 on 18p11.31).
None of these markers were previously described as modi-
ﬁers of AD risk or onset age. Interestingly, with theber 7, 2008
exception of rs2049161, all SNPs are located either in or
close to previously described early- and late-onset AD link-
age regions.7,23 Analyses using affection status and age of
onset as separate phenotypes revealed that SNP
rs11159647 on chromosome 14q31.2 was primarily associ-
ated with age of onset ([two-tailed] p ¼ 0.006, median re-
duction in onset age 1.1 years; odds ratio [OR] ~1.4;
Figure 2A), whereas the remaining markers only showed
association in the analyses using affection status (ORs
ranging from ~1.1 to 1.3). All markers showed their stron-
gest signals in an additive transmissionmodel, with the ex-
ception of SNP rs3826656 on chromosome 19q13.33, for
which dominant transmission of the minor allele yielded
the strongest association. None of the fourmarkers showed
evidence of association in NIMH families of African Amer-
ican descent, possibly because of lower power in that this
subset only consists of 24 families (data not shown).
We next assessed whether any of the non-APOE signals
also show association with AD in three additional and
independently collected family samples of self-reported
European ancestry (‘‘NIA,’’ ‘‘NCRAD,’’ and ‘‘CAG’’) by gen-
otyping the same SNPs for which association was observed
in the genome-wide analyses. The vast majority of these
families are made up of sibships (either concordant or dis-
cordant for AD), with a total of 2689 individuals (1816 af-
fecteds and 845 unaffecteds). Upon combining results
across all three replication samples (with Fisher’s com-
bined probability test) we observed signiﬁcant association
with the multivariate phenotype for two of the four SNPs
tested ([one-tailed] p values 0.00002 [rs11159647] and
0.007 [rs3826656]; Table 1; Figure 2B). A third SNP showed
a trend toward association in the replication samples but
Figure 1. Q-Q Plot of Markers Tested in the GWA Screening
Phase
Distribution of FBAT-GEE p values for all 404,604 SNPs on the 500K
array with R20 informative families as Q-Q plot depicting
observed versus expected p values.The Americaonly in the analyses using affection status as phenotype
([one-tailed] p ¼ 0.06 [rs179943]; Table 1). The fourth
SNP (rs2049161), which was only marginally associated
with AD in the primary 500K screen, did not show any
consistent pattern of association in the replication sam-
ples. We next investigated whether any of the four SNPs
showed association in the two recently published AD
GWA analyses, for which genotype data were made pub-
licly available. Because these data did not include sub-
ject-level age-of-onset information, only test statistics us-
ing affection status could be calculated (Table 2).
rs11159647 on chromosome 14q, the SNP demonstrating
the strongest association with AD in our family-based
Figure 2. Kaplan-Meier Survival Curves for rs11159647 in
500K Screening Sample and Combined Follow-Up Data Set
Dotted lines represent carriers of the A/A genotype, broken lines
are A/G-carriers, solid lines are G/G-carriers. (A) shows the NIMH
sample used in the 500K screen. (B) shows the sample after
combining all follow-up samples (NIA, NCRAD, and CAG).n Journal of Human Genetics 83, 623–632, November 7, 2008 627
Table 1. Results of Whole-Genome Association Screening and Follow-Up Analyses using Family-based Samples
SNP Model














FBAT-GEE add 0.001 200 0.000005 176 0.045 163 0.35 89 0.00002 428 0.000002 628
Affection
status
add 0.05 128 0.4 104 0.02 100 0.2 89 0.05 293 0.07 421
Age of onset add 0.006 200 0.002 176 0.0035 163 0.2 89 0.0001 428 0.00005 628
rs179943
FBAT-GEE add 0.002 76 0.065 48 0.8* 53 0.2 29 0.15 130 0.008 206
Affection
status
add 0.007 55 0.04 27 0.8* 31 0.07 29 0.06 87 0.008 142
Age of onset add 1 76 0.2 48 0.9* 53 0.1 29 0.25 130 0.4 206
rs3826656
FBAT-GEE dom 0.000004 123 0.15 127 0.25 110 0.004 75 0.007 312 0.000006 435
Affection
status
dom 0.02 90 0.03 79 0.4 69 0.035 74 0.015 222 0.01 312
Age of onset dom 0.6 123 0.07 127 0.3 110 0.07 75 0.05 312 0.3 435
rs2049161
FBAT-GEE add 0.002 122 0.8* 129 0.8* 109 0.04 57 0.3 295 0.006 417
Affection
status
add 0.04 78 0.9* 83 0.75* 72 0.25 53 0.7 208 0.1 286
Age of onset add 1 122 0.9* 129 0.6* 109 0.2 57 0.65 295 0.7 417
FBAT-GEE refer to analyses using affection status and age at onset as a multivariate phenotype. The p values are nominal and two-tailed for results
including NIMH families, and one-tailed for results solely based on the replication samples (NIA, NCRAD, and CAG). The p values for combined samples
are one-tailed for the replication samples only (‘‘Replication’’) and two-tailed for NIMH and replication samples combined (‘‘NIMH þ Replication’’) and
calculated by methods described previously (see Fisher22). Fams, informative families. Asterisks represent association with opposite allele as compared
to 500K analyses (associated alleles in 500K analyses were ‘‘A’’ [rs11159647], ‘‘T’’ [rs179943], ‘‘G’’ [rs3826656], and ‘‘C’’ [rs2049161]). Age of onset coding
based on Wilcoxon statistic. Thresholds to achieve genome-wide significance on the basis of the method by Ionita-Laza et al.19 are p % 5 3 103 for
markers rs11159647, rs179943, and rs2049161, and p% 4.88 3 106 for rs3826656.analyses, revealed nominally signiﬁcant association with
the same allele in the TGEN data set ([one-tailed] p ¼
0.04; see Reiman et al.8). Meanwhile, rs2049161 on chro-
mosome 18p showed nominally signiﬁcant association in
the GSK data set ([one-tailed] p ¼ 0.045; see Li et al.10).
Interestingly, this latter SNP was the only marker not628 The American Journal of Human Genetics 83, 623–632, Novembshowing any consistent evidence of association in our
family-based replication samples (see above). rs179943
did not show evidence of association in either of the two
previously published GWA screens; no analyses could be
performed for rs3826656 because it was missing from
both case-control GWA data sets.Table 2. Comparison of Family-Based versus Published Case-Control GWA Findings for the Signals Identified in the NIMH 500K
Screen
SNP Model
NIMH (500K) TGEN8 GSK10
p (two-tailed) Fams p (one-tailed) n (AD þ CTRL) p (one-tailed) n (AD þ CTRL)
rs11159647, with affection status add 0.05 128 0.04 1384 0.9* 1315
rs179943, with affection status add 0.007 55 0.8* 1376 0.5* 1368
rs3826656, with affection status dom 0.02 90 N.A. N.A. N.A. N.A.
rs2049161, with affection status add 0.04 78 0.2 1407 0.045 1386
Family-based (NIMH) p values are two sided and identical to those of Table 1. Case-control (TGEN7 and GSK10) p values are one sided, on the basis of
an allelic chi-square test (1 d.f.) with the genotype frequencies of the original publications (note that the FBAT-GEE and age of onset statistics could
not be computed here because of the lack of onset-age data in the original reports). The results presented in this table are based on the complete
data sets made available by the authors of the respective studies. Fams, informative families. The asterisks represent association with opposite allele
as compared to 500K analyses (see identity of associated alleles in legend to Table 1). ‘‘N.A.’’ represents no data provided for this marker. Significant
p values are represented in bold.er 7, 2008
In two separately performed projects,24,25 we assessed
whether any of the currently most promising putative
AD susceptibility loci (based on a recent freeze of the
AlzGene database), including all ﬁve recently pinpointed
by the two high-density case-control GWA studies,8,10
showed association in the four family data sets tested
here. After combining results across all four samples with
the same analytical methodology applied here, we ob-
served nominally signiﬁcant association with variants in
ACE (MIM 106180), CHRNB2 (MIM 118507), GAB2 (MIM
606203), TF (MIM 190000), and an as-yet-unidentiﬁed
locus on chromosome 7p15.2. Of these, GAB28 and the
7p15.2 locus9 were originally implicated by GWA associa-
tion analyses. Note, however, that the level of statistical
support for each of these loci was several orders of magni-
tude smaller (i.e., combined p values ranging between
0.03 and 0.002) than that observed for the chromosome
14 locus identiﬁed here. Variants in other recently reported
potential AD genes, such as SORL1 (MIM 602005) and
GOLM1 (a.k.a. GOLPH2 [MIM 606804]; see AlzGene data-
base for details), did not show any signiﬁcant evidence in
these analyses.
Our ﬁndings are noteworthy for a number of reasons.
First, to our knowledge, this is the ﬁrst GWA analysis using
family-based methods to be reported in the ﬁeld of AD. For
two of the four non-APOE SNPs, the initial evidence for
genetic association was replicated in three independent
collections of AD families of self-reported European de-
scent, whereas a third SNP showed at least a trend toward
association in the analyses limited to affection status.
Moreover, for the SNP exhibiting the strongest and most
consist family-based association with AD in our analyses,
rs11159647, we also observed statistically signiﬁcant asso-
ciation of the same risk allele with AD in an independent
collection of cases and controls that had been probed
with the same 500K SNP array.8 Collectively, these data
strongly argue for the presence of a genuine AD susceptibil-
ity locus in the vicinity of marker rs11159647 on chromo-
some 14q31.2. In addition, our analyses highlight two
further putative AD loci located on chromosomes 6p22
and 19q13. Second, we used a quantitative analysis
approach combining the twomost widely available pheno-
types in AD samples, i.e., age of onset and affection status.
This has the advantage of increasing power while ensuring
consistency of the ﬁndings across both phenotypes.18,21
Power calculations reveal that minimally ~700 combined
cases and controls are required for detection of the addi-
tively transmitted rs11159647 risk effect (i.e., an allelic OR
of ~1.4) at a ¼ 0.05 in order to achieve 80% power and
minimally ~2,300 (~8,600) samples for the more modest
risk effects of SNPs rs3826656 and rs179943. Third, the
association signal for rs11159647 maps to the distal end
of a genetic linkage region identiﬁed earlier by our group
in a whole-genome linkage screen of the NIMH sample,12
as well as in an independent collection of Caribbean His-
panic families that used age of onset as a phenotype.26 In
our own previous report, most of the linkage evidence orig-The Americinated from families with an ‘‘early/mixed’’ onset age, i.e.,
those families in which at least one affected family mem-
ber, showed an onset age prior to 65 years.23 This is in
good agreement with the decrease in onset age observed
here in individuals carrying the A allele at rs11159647. A
similar observation was made with the whole-genome
linkage signal encompassing the APOE region on chromo-
some 19q13, which was also most pronounced in families
with an ‘‘early/mixed’’ onset age.23 Interestingly, the other
two putative signals implied by our GWA and follow-up
analyses map to chromosomes 6p22 and 19q13, which
were also highlighted by genome-wide linkage analyses
of our and other groups.7,23
Despite the compelling statistical and genetic epidemio-
logical evidence strongly implicating the presence of a
putative AD gene on chromosome 14q, and possibly addi-
tional loci on chromosomes 6p22 and 19q13, the potential
functional and pathophysiological consequences of our
ﬁndings remain elusive. According to the UCSC genome
browser (hg18, NCBI Build 36.1), the genomic region in
the vicinity of the AD-associated SNP, rs11159647, on
chromosome 14q31 does not contain any known RefSeq
genes. This SNP resides at position 83,844,962 bp on chro-
mosome 14 in an intron of the Genscan-predicted gene,
NT_026437.1360 (Figure 3), which spans 723,153 bp.
The coding region of this predicted gene in the region of
rs11159647 reveals no signiﬁcant homologies to other
genes or coding regions in GenBank. Interestingly, the 30
end of this predicted gene contains exons with homology
to the C2H2-type kruppel-like zinc-ﬁnger protein 268
(ZNF268 [MIM 604753]; see Gou et al.27). However, the
AD-associated SNP, rs11159647, is >350 Kb from the
ZNF268 homologous region, and SNPs in this region reveal
no linkage disequilibrium with rs11159647. There are
three expressed sequence tags (ESTs) residing within 60
Kb on either side of rs11159647. These include ESTs,
M85511, CA390254, and AI003603. All three ESTs are ex-
pressed in the brain and are encoded within the same re-
gion as the predicted gene, NT_026437.1360. However,
the predicted exon structure of these ESTs does not align
with the predicted exons of NT_026437.1360. Thus, these
ESTsmay represent exons of separate gene(s) in this region,
which are expressed in the brain. It is also worth noting
that SNPs in these three ESTs display varying degrees of
LD with rs11159647. BLAST analyses of these ESTs reveal
no signiﬁcant homologies with any known genes. Figure 3
illustrates the LD patterns in the region surrounding
rs11159647, whereas Figure 4 shows that there are several
other SNPs within ~200 kb yielding evidence for associa-
tion with AD on the 500K array, thereby delineating the
chromosomal region that should be targeted by subse-
quent ﬁne-mapping efforts. SNP rs179943, on 6p22.3 at
position 16,506,297 bp, resides within an intron of the
ataxin 1 (ATXN1) gene, in which an elongated polyglut-
amine tract causes the progressive neurodegenerative dis-
ease spinocerebellar ataxia (SCA1 [MIM 164400]), charac-
terized by progressive degeneration of the cerebellum,an Journal of Human Genetics 83, 623–632, November 7, 2008 629
Figure 3. Genomic Context of the Chromosome 14q31 Association Signal
Linkage disequilibrium structure and location of Genscan Gene predictions (NTSs) in a 500 kb interval encompassing rs11159647 on
chromosome 14q31.2.brain stem, and spinal cord.28 SNP, rs3826656, on 19q13.33
at position 56,418,175 bp, resides in a region that contains
no known RefSeq genes. However, this SNP resides in a pre-
dicted Genscan gene, NT_011109.848, spanning 126,319
bp. The 3’ portion of this locus overlaps with the gene en-
coding human protein CD33 (MIM 159590). CD33, also
known as SIGLEC3, encodes a cell-surface receptor on cells
of monocytic or myeloid lineage. It is also a member of the
SIGLEC family of lectins that bind sialic acid and regulate
the innate immune system via the activation of caspase-de-
pendent and caspase-independent cell-death pathways.29
Finally, rs2049161, on 18p11.31 at position 4,117,583 bp,630 The American Journal of Human Genetics 83, 623–632, Novembresides within an intron of BC040718, a gene of currently
unknown function.
In conclusion, to our knowledge this is the ﬁrst study to
employ a family-based GWA approach to AD. In addition
to a likely APOE 34-related effect, we obtained compelling
evidence for genome-wide signiﬁcant association between
ADandat least twoadditional SNPs. The replicationof these
associations in three independent AD family samples—and
in the caseof rs11159647 also inone independent case-con-
trol GWA data set—strongly implies the existence of AD
susceptibility loci thatwarrant followup in additional inde-
pendent samples as well as in functional genomic analyses.er 7, 2008
Figure 4. Association Results of
Markers within 500 kb of the Chromo-
some 14q31 Association Signal
Distribution of association results of SNPs
on the 500K array within 5250 kb of SNP
rs11159647 on chromosome 14q31 show-
ing genome-wide significance in the NIMH-
CAU sample (FBAT-GEE statistic, additive
model).Supplemental Data
Supplemental Data include two tables and ﬁve ﬁgures and can be
found with this article online at http://www.ajhg.org/.
Acknowledgments
The authors wish to thank all families for participating in this
study. This work was sponsored by grants from the Cure Alzheimer
Fund (as part of the ‘‘Alzheimer Genome Project’’), the NIMH, and
the Extendicare Foundation.Work completed at TorreyPines Ther-
apeutics and was funded by Eisai. L.B. and R.E.T. are consultants
to, and equity holders in, TorreyPines Therapeutics and Prana Bio-
technology. R.E.T. is also a consultant to Prana Biotechnology.
R.E.T. is a cofounder of both TorreyPines Therapeutics and Prana
Biotechnology. K.L.O., K.E., X.W., D.H.-L., M.R., K.D.B., and S.W.
are employees of, and hold stock options in, TorreyPines Thera-
peutics. K.E. and S.W. also hold stock in Merck.
Received: July 8, 2008
Revised: September 18, 2008
Accepted: October 9, 2008
Published online: October 30, 2008
Web Resources




International HapMap Consortium, http://www.hapmap.org
National Cell Repository for Alzheimer’s Disease (NCRAD), http://
www.ncrad.org




1. Goate, A., Chartier-Harlin, M.C., Mullan, M., Brown, J.,
Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N.,
James, L., et al. (1991). Segregation of a missense mutationThe Americanin the amyloid precursor protein gene with familial
Alzheimer’s disease. Nature 349, 704–706.
2. Levy-Lahad, E.,Wasco,W., Poorkaj, P., Romano,D.M.,Oshima,
J., Pettingell,W.H., Yu, C.E., Jondro, P.D., Schmidt, S.D.,Wang,
K., et al. (1995). Candidate gene for the chromosome 1 familial
Alzheimer’s disease locus. Science 269, 973–977.
3. Rogaev, E.I., Sherrington, R., Rogaeva, E.A., Levesque, G.,
Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T.,
et al. (1995). Familial Alzheimer’s disease in kindreds with
missense mutations in a gene on chromosome 1 related to
the Alzheimer’s disease type 3 gene. Nature 376, 775–778.
4. Sherrington, R., Rogaev, E.I., Liang, Y., Rogaeva, E.A., Levesque,
G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995).
Cloning of a gene bearing missense mutations in early-onset
familial Alzheimer’s disease. Nature 375, 754–760.
5. Saunders, A.M., Strittmatter, W.J., Schmechel, D., George-Hys-
lop, P.H., Pericak-Vance,M.A., Joo, S.H., Rosi, B.L., Gusella, J.F.,
Crapper-MacLachlan, D.R., Alberts, M.J., et al. (1993).
Association of apolipoprotein E allele epsilon 4 with late-onset
familial and sporadic Alzheimer’s disease. Neurology 43,
1467–1472.
6. Gatz, M., Reynolds, C.A., Fratiglioni, L., Johansson, B.,
Mortimer, J.A., Berg, S., Fiske, A., and Pedersen, N.L. (2006).
Role of genes and environments for explaining Alzheimer
disease. Arch. Gen. Psychiatry 63, 168–174.
7. Bertram, L., McQueen,M.B., Mullin, K., Blacker, D., and Tanzi,
R.E. (2007). Systematic meta-analyses of Alzheimer disease ge-
netic association studies: the AlzGene database. Nat. Genet.
39, 17–23.
8. Reiman, E.M., Webster, J.A., Myers, A.J., Hardy, J., Dunckley,
T., Zismann, V.L., Joshipura, K.D., Pearson, J.V., Hu-Lince,
D., Huentelman, M.J., et al. (2007). GAB2 alleles modify Alz-
heimer’s risk in APOE epsilon4 carriers. Neuron 54, 713–720.
9. Grupe, A., Abraham, R., Li, Y., Rowland, C., Hollingworth, P.,
Morgan, A., Jehu, L., Segurado, R., Stone, D., Schadt, E., et al.
(2007). Evidence for novel susceptibility genes for late-onset
Alzheimer’s disease from a genome-wide association study of
putative functional variants. Hum. Mol. Genet. 16, 865–873.
10. Li, H., Wetten, S., Li, L., St Jean, P.L., Upmanyu, R., Surh, L.,
Hosford, D., Barnes, M.R., Briley, J.D., Borrie, M., et al.
(2008). Candidate single-nucleotide polymorphisms from a
genomewide association study of Alzheimer disease. Arch.
Neurol. 65, 45–53.Journal of Human Genetics 83, 623–632, November 7, 2008 631
11. McKhann, G., Drachman, D., Folstein, M., Katzman, R.,
Price, D., and Stadlan, E.M. (1984). Clinical diagnosis of
Alzheimer’s disease: Report of the NINCDS-ADRDA Work
Group under the auspices of Department of Health and
Human Services Task Force on Alzheimer’s Disease. Neurol-
ogy 34, 939–944.
12. Blacker, D., Haines, J.L., Rodes, L., Terwedow, H., Go, R.C.,
Harrell, L.E., Perry, R.T., Bassett, S.S., Chase, G., Meyers, D.,
et al. (1997). ApoE-4 and age at onset of Alzheimer’s disease:
The NIMH genetics initiative. Neurology 48, 139–147.
13. Bertram, L., Hiltunen, M., Parkinson, M., Ingelsson, M.,
Lange, C., Ramasamy, K., Mullin, K., Menon, R., Sampson,
A.J., Hsiao, M.Y., et al. (2005). Family-based association be-
tween Alzheimer’s disease and variants in UBQLN1. N. Engl.
J. Med. 352, 884–894.
14. Rabbee, N., and Speed, T.P. (2006). A genotype calling algo-
rithm for affymetrix SNP arrays. Bioinformatics 22, 7–12.
15. Chen, X., Levine, L., and Kwok, P.Y. (1999). Fluorescence po-
larization in homogeneous nucleic acid analysis. Genome
Res. 9, 492–498.
16. Lange, C., DeMeo, D., Silverman, E.K., Weiss, S.T., and Laird,
N.M. (2004). PBAT: tools for family-based association studies.
Am. J. Hum. Genet. 74, 367–369.
17. Laird, N.M., Horvath, S., and Xu, X. (2000). Implementing
a uniﬁed approach to family-based tests of association. Genet.
Epidemiol. 19 (Suppl 1), S36–S42.
18. Lange, C., Silverman, E.K., Xu, X., Weiss, S.T., and Laird, N.M.
(2003). A multivariate family-based association test using gen-
eralized estimating equations: FBAT-GEE. Biostatistics 4, 195–
206.
19. Ionita-Laza, I., McQueen, M.B., Laird, N.M., and Lange, C.
(2007). Genomewide weighted hypothesis testing in family-
based association studies, with an application to a 100K
scan. Am. J. Hum. Genet. 81, 607–614.
20. Van Steen, K., McQueen, M.B., Herbert, A., Raby, B., Lyon, H.,
Demeo, D.L., Murphy, A., Su, J., Datta, S., Rosenow, C., et al.
(2005). Genomic screening and replication using the same
data set in family-based association testing. Nat. Genet. 37,
683–691.632 The American Journal of Human Genetics 83, 623–632, Novemb21. Jiang, H., Harrington, D., Raby, B.A., Bertram, L., Blacker, D.,
Weiss, S.T., and Lange, C. (2006). Family-based association
test for time-to-onset data with time-dependent differences
between the hazard functions. Genet. Epidemiol. 30, 124–
132.
22. Fisher, R.A. (1925). Statistical Methods for Research Workers
(Edinburgh: Oliver and Boyd).
23. Blacker, D., Bertram, L., Saunders, A.J., Moscarillo, T.J., Albert,
M.S., Wiener, H., Perry, R.T., Collins, J.S., Harrell, L.E., Go,
R.C., et al. (2003). Results of a high-resolution genome screen
of 437 Alzheimer’s disease families. Hum. Mol. Genet. 12, 23–
32.
24. Schjeide, B.-M.M., McQueen, M.B., Mullin, K., Divito, J., Ho-
gan, M.F., Parkinson, M., Lange, C., Blacker, D., Tanzi, R.,
and Bertram, L. (2008). Assessment of Alzheimer’s disease
case-control associations using family-based methods. Neuro-
genetics, in press. Published online October 2, 2008. 10.1007/
s10048-008-0151-3.
25. Schjeide, B.-M.M., Hooli, B., Parkinson, M., Hogan, M.F., Div-
ito, J., Mullin, K., Blacker, D., Tanzi, R., and Bertram, L. (2009).
Follow-up of genome-wide association results suggests GAB2
as an Alzheimer’s disease susceptibility gene. Arch. Neurol.,
in press.
26. Lee, J.H., Barral, S., Cheng, R., Chacon, I., Santana, V., Wil-
liamson, J., Lantigua, R., Medrano, M., Jimenez-Velazquez,
I.Z., Stern, Y., et al. (2008). Age-at-onset linkage analysis in Ca-
ribbean Hispanics with familial late-onset Alzheimer’s disease.
Neurogenetics 9, 51–60.
27. Gou, D.M., Sun, Y., Gao, L., Chow, L.M., Huang, J., Feng, Y.D.,
Jiang, D.H., and Li, W.X. (2001). Cloning and characterization
of a novel Kruppel-like zinc ﬁnger gene, ZNF268, expressed
inearlyhumanembryo.Biochim.Biophys.Acta1518, 306–310.
28. Orr, H.T., and Zoghbi, H.Y. (2001). SCA1 molecular genetics:
a history of a 13 year collaboration against glutamines.
Hum. Mol. Genet. 10, 2307–2311.
29. von Gunten, S., and Simon, H.U. (2006). Sialic acid binding
immunoglobulin-like lectins may regulate innate immune re-
sponses by modulating the life span of granulocytes. FASEB J.
20, 601–605.er 7, 2008
